亿帆医药股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）于2026年2月12日收到公司控 股股东程先锋先生的通知，获悉程先锋先生将其持有的公司股份部分办理了质押 展期，具体事项如下： 二、股东股份累计质押的情况 截至本公告披露日，程先锋先生及其一致行动人所持质押股份情况如下： 证券代码：002019 证券简称：亿帆医药 公告编号：2026-011 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 本次质 押数量 （股） 占其所 持股份 比例 占公 司总 股本 比例 是否为限售 股（如是， 注明限售类 型） 是否为 补充质 押 质押起 始日 原质押 到期日 展期到 期日 质权人 质押用途 程先锋 是 22,500,0 00 4.53% 1.85% 是（高管锁 定股） 否 2024 年 2 月 21 日 2026 年 2 月 21 日 2027 年 2 月 19 日 招商证券股 份有限公司 用于自身 生产经营 合计 -- 22,500,0 00 4.53% 1.85% ...

Group 1 - The core point of the article is that the controlling shareholder of Yifan Pharmaceutical, Cheng Xianfeng, has extended the pledge of 22.5 million shares, which represents 4.53% of his holdings and 1.85% of the company's total share capital [1] - The new pledge expiration date is set for February 19, 2027, while the previous expiration date was February 21, 2026 [1] - As of the announcement date, Cheng Xianfeng and his concerted parties hold a total of 521,588,207 shares, accounting for 42.88% of the total share capital [1] Group 2 - A total of 70 million shares have been pledged cumulatively, which represents 13.42% of Cheng Xianfeng's holdings and 5.75% of the company's total share capital [1]

Group 1 - Company SciGen Pte. Ltd., a wholly-owned subsidiary of Yifan Pharmaceutical, has received approval from the Health Sciences Authority (HSA) of Singapore for the marketing registration of its pharmaceutical product, Norepinephrine SciGen, a concentrated solution for injection [1] - The product is indicated for the management of severe acute hypotension in adults and was approved domestically in March 2023, with the registration application submitted to HSA in December 2023 [1] - The approval supports the company's strategy for "full-category, multi-region" international expansion, with domestic production lines receiving international certification [1] Group 2 - The approval is not expected to have a significant short-term impact on the company's operating performance, but successful commercialization in the future could yield positive effects [1] - The operational situation may be influenced by overseas policies and exchange rate fluctuations, indicating some uncertainty for investors [1]

Core Viewpoint - Company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its pharmaceutical product, concentrated solution of racemic norepinephrine for injection, which is intended for the management of severe acute hypotension in adults [1] Group 1 - The product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1] - The approval marks a significant milestone for the company's expansion into the Singapore market [1]

Group 1 - The company, Yifan Pharmaceutical (002019), emphasizes its commitment to a long-term strategy focused on "innovation and internationalization" [1] - The company plans to concentrate more on its existing synthetic biology and pharmaceutical sectors in the future [1]

Core Viewpoint - Yifan Pharmaceutical stated that according to current accounting standards, recognized impairment of intangible assets cannot be reversed, but the company will continue to strive to further explore the market value of the product [2] Group 1 - Yifan Pharmaceutical has acknowledged the impairment of intangible assets and clarified that it cannot be reversed under existing accounting regulations [2] - The company is committed to enhancing the market value of its products despite the impairment [2]

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) reported a total of 48,356 shareholders as of January 20, 2026 [1]

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - The company's subsidiary, SciGen Pte. Ltd., is responsible for the newly approved product [1] - The approved product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1]

Core Viewpoint - Yifan Pharmaceutical's product Yilishu is still in the early stages of market introduction in the United States, with sales volume dependent on procurement agreements and actual orders rather than terminal sales [2] Group 1 - Yifan Pharmaceutical responded to investor inquiries on February 6, indicating that the procurement volume of Yilishu's U.S. partner is based on agreements and orders [2] - The product has been on the U.S. market for less than a year and is currently in the initial ramp-up phase [2]

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - YiFan Pharmaceutical's wholly-owned subsidiary, SciGen Pte. Ltd., has been granted a market registration approval by HSA [1] - The approved product, racemic norepinephrine injection solution, is used for blood pressure control in adults experiencing severe acute hypotension [1] - The drug is designed to elevate blood pressure levels in critical situations [1]